Amoxicillin-resistant Streptococcus pneumoniae can be resensitized by targeting the mevalonate pathway as indicated by sCRilecs-seq.

Abstract

Antibiotic resistance in the important opportunistic human pathogen Streptococcus pneumoniae is on the rise. This is particularly problematic in the case of the β-lactam antibiotic amoxicillin, which is the first-line therapy. It is therefore crucial to uncover targets that would kill or resensitize amoxicillin-resistant pneumococci. To do so, we developed a genome-wide, single-cell based, gene silencing screen using CRISPR interference called sCRilecs-seq (subsets of CRISPR interference libraries extracted by fluorescence activated cell sorting coupled to next generation sequencing). Since amoxicillin affects growth and division, sCRilecs-seq was used to identify targets that are responsible for maintaining proper cell size. Our screen revealed that downregulation of the mevalonate pathway leads to extensive cell elongation. Further investigation into this phenotype indicates that it is caused by a reduced availability of cell wall precursors at the site of cell wall synthesis due to a limitation in the production of undecaprenyl phosphate (Und-P), the lipid carrier that is responsible for transporting these precursors across the cell membrane. The data suggest that, whereas peptidoglycan synthesis continues even with reduced Und-P levels, cell constriction is specifically halted. We successfully exploited this knowledge to create a combination treatment strategy where the FDA-approved drug clomiphene, an inhibitor of Und-P synthesis, is paired up with amoxicillin. Our results show that clomiphene potentiates the antimicrobial activity of amoxicillin and that combination therapy resensitizes amoxicillin-resistant S. pneumoniae. These findings could provide a starting point to develop a solution for the increasing amount of hard-to-treat amoxicillin-resistant pneumococcal infections.

• Authors: Liselot Dewachter, Julien Dénéréaz, Xue Liu, Vincent de Bakker, Charlotte Costa, Mara Baldry, Jean-Claude Sirard, Jan-Willem Veening
• Journal: eLife (Elife) Vol. 11 (06 24 2022) ISSN: 2050-084X [Electronic] England
• PMID: 35748540 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022, Dewachter et al.

Chemical References

• Anti-Bacterial Agents
• Amoxicillin
• Mevalonic Acid

Topics

• Amoxicillin (pharmacology)
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Drug Resistance, Microbial
• Humans
• Mevalonic Acid
• Pneumococcal Infections (drug therapy)
• Streptococcus pneumoniae (genetics)